Please login to the form below

Not currently logged in
Email:
Password:

Elijah Cummings

This page shows the latest Elijah Cummings news and features for those working in and with pharma, biotech and healthcare.

Teva among generic drugmakers hoping to settle US antitrust probe

Teva among generic drugmakers hoping to settle US antitrust probe

The politicians, including potential presidential candidate Bernie Sanders and Chairman of the House Committee on Oversight and Reform Elijah Cummings, asked the company for the same data on sales and expenditures

Latest news

  • US politicians round on generics firms for blocking drug pricing probe US politicians round on generics firms for blocking drug pricing probe

    That’s when Elijah Cummings, the Chairman of the House Committee on Oversight and Reform, and Sanders wrote to the companies seeking information about the “dramatic increase in generic drug prices”. ... In the letter, Cummings and Sanders note that

  • Marathon pauses Emflaza launch amid pricing furore Marathon pauses Emflaza launch amid pricing furore

    dystrophy. US politicians including Senator Bernie Sanders and Representative Elijah Cummings have the company firmly in their sights, saying that the pricing is "unconscionable", and suggesting the firm is abusing ... premiums. Sanders and Cummings say

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

New Playbook Alert: Virtual Patient Engagement
...
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....